Drug metabolism in liver disease.
作者信息
Prescott L F, Forrest J A, Adjepon-Yamoah K K, Finlayson N D
出版信息
J Clin Pathol Suppl (R Coll Pathol). 1975;9:62-5.
Abstract
摘要
相似文献
1
Drug metabolism in liver disease.肝脏疾病中的药物代谢
J Clin Pathol Suppl (R Coll Pathol). 1975;9:62-5.
2
3
Liver disease and drug therapy.肝脏疾病与药物治疗
Med Clin North Am. 1974 Sep;58(5):1051-7. doi: 10.1016/s0025-7125(16)32100-9.
4
Editorial: Drug metabolism in disease.
Lancet. 1974 Apr 27;1(7861):790-1.
5
Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.慢性肝病中安替比林、对乙酰氨基酚和利多卡因的消除情况。
Br Med J. 1977 May 28;1(6073):1384-7. doi: 10.1136/bmj.1.6073.1384.
6
[Drug metabolism in liver diseases].[肝脏疾病中的药物代谢]
Z Gastroenterol Verh. 1979;16:42-7.
7
Impairment of drug elimination in patients with liver disease.肝病患者药物消除功能受损。
Int J Clin Pharmacol Ther Toxicol. 1985 Jan;23(1):28-32.
8
Impairment of drug metabolism in polycystic non-parasitic liver disease.多囊性非寄生虫性肝病中药物代谢的损害。
Br J Clin Pharmacol. 1979 Oct;8(4):331-5. doi: 10.1111/j.1365-2125.1979.tb04714.x.
9
[Recent findings on the hepatotoxicity of drugs].[药物肝毒性的最新研究发现]
Recenti Prog Med. 1985 Nov;76(11):598-605.
10
[Induction of drug-catabolizing enzymes in chronic alcoholics].[慢性酒精中毒患者药物代谢酶的诱导作用]
Arch Biochem Biophys. 1974 Jan;160(1):907-8.
引用本文的文献
1
N-Acetylcysteine for Preventing Acetaminophen-Induced Liver Injury: A Comprehensive Review.N-乙酰半胱氨酸预防对乙酰氨基酚诱导的肝损伤：一项综述
Front Pharmacol. 2022 Aug 10;13:828565. doi: 10.3389/fphar.2022.828565. eCollection 2022.
2
Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan.内皮素受体拮抗剂马昔腾坦的临床药代动力学和药效学
Clin Pharmacokinet. 2015 May;54(5):457-71. doi: 10.1007/s40262-015-0255-5.
3
Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma.脂蛋白(a)作为肝细胞癌残余肝功能的潜在标志物。
Indian J Med Paediatr Oncol. 2011 Apr;32(2):71-5. doi: 10.4103/0971-5851.89775.
本文引用的文献
1
RATE OF METABOLISM OF TOLBUTAMIDE IN TEST SUBJECTS WITH LIVER DISEASE OR WITH IMPAIRED RENAL FUNCTION.患有肝脏疾病或肾功能受损的受试对象中甲苯磺丁脲的代谢率
Am J Med Sci. 1964 Dec;248:657-9. doi: 10.1097/00000441-196412000-00004.
2
Conjugation of N-acetyl-p-aminophenol (N.A.P.A.) in adult liver patients.成年肝病患者体内对乙酰氨基酚（N.A.P.A.）的结合反应
Acta Hepatosplenol. 1969 Jan-Feb;16(1):11-8.
3
The effects of aliphatic halogenated hydrocarbons on hepatic drug metabolism.脂肪族卤代烃对肝脏药物代谢的影响。
Biochem Pharmacol. 1968 Jul;17(7):1269-78. doi: 10.1016/0006-2952(68)90064-6.
4
Effect of age and sex on human drug metabolism.年龄和性别对人体药物代谢的影响。
Br Med J. 1971 Sep 11;3(5775):607-9. doi: 10.1136/bmj.3.5775.607.
5
Metabolism of amylobarbitone in patients with chronic liver disease.慢性肝病患者中异戊巴比妥的代谢
Br J Pharmacol. 1972 Mar;44(3):549-60. doi: 10.1111/j.1476-5381.1972.tb07292.x.
6
The rate of procaine hydrolysis in serum of normal subjects and diseased patients.正常受试者和患病患者血清中普鲁卡因的水解速率。
Clin Pharmacol Ther. 1972 Mar-Apr;13(2):279-84. doi: 10.1002/cpt1972132279.
7
Plasma half-life of phenylbutazone in patients with impaired liver function.肝功能受损患者中保泰松的血浆半衰期。
Clin Pharmacol Ther. 1974 Feb;15(2):171-7. doi: 10.1002/cpt1974152171.
8
The effects of hepatic and renal damage on paracetamol metabolism and excretion following overdosage. A pharmacokinetic study.过量用药后肝损伤和肾损伤对扑热息痛代谢及排泄的影响。一项药代动力学研究。
Br J Pharmacol. 1973 Dec;49(4):602-13. doi: 10.1111/j.1476-5381.1973.tb08536.x.
9
Determinants of serum antipyrine half-lives in patients with liver disease.肝病患者血清安替比林半衰期的决定因素。
Gut. 1973 Jul;14(7):569-73. doi: 10.1136/gut.14.7.569.
10
Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.利多卡因在人类晚期心力衰竭、肝脏疾病和肾衰竭中的药代动力学。
Ann Intern Med. 1973 Apr;78(4):499-508. doi: 10.7326/0003-4819-78-4-499.
Zotero 插件